Close Menu

NEW YORK – Resolution Biosciences said Monday that it has entered an agreement with Laboratory Corporation of America to commercialize its Resolution ctDx Lung test.

LabCorp plans to launch the test in the first half of 2020 and will be its exclusive provider with Resolution performing the assay as a laboratory-developed test out of its CLIA facility.

The test uses next-generation sequencing to look for actionable mutations in cell-free DNA from non-small cell lung cancer patients.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
LGC SeraCare Life Sciences

This webinar features a panel of industry stakeholders in cancer diagnostics, proficiency testing and clinical care who will discuss the promise and challenges of liquid biopsy technologies in disease diagnosis, monitoring, and patient care management.

Sponsored by

The COVID-19 pandemic created a paradigm shift in modern healthcare, where regulations, protocols, and mindsets had to be reworked in just a matter of months to keep up with the pace of the virus.